SACCHAROMYCES CEREVISIAE HOST-VECTOR SYSTEMS EXEMPTION FROM NIH DNA
SACCHAROMYCES CEREVISIAE HOST-VECTOR SYSTEMS EXEMPTION FROM NIH DNA guidelines would be extended to experiments on cell lines of the yeast other than "laboratory strains" under a proposal to be considered by the agency's rDNA Advisory Committee (RAC) Sept. 23. The proposal by BioTechnica Internatl. of Cambridge, Massachusetts is explained in an Aug. 19 Federal Register notice. The proposal seeks to amend current NIH guidelines, which now exempt rDNA experiments using S. cerevisiae host-vector systems from the guidelines, "provided that laboratory strains are used." Currently, for exempt laboratory experiments, BL1 (biosafety level) physical containment conditions are recommended. For large-scale fermentation experiments, BLl-LS physical containment is recommended. The guidelines stipulate exceptions to the exemption, which the proposal does not seek to change. BioTechnica is also proposing a new exemption from the NIH guidelines for DNA experiments which use S. uvarum host-vector systems. RAC will also consider scientific requests for permission to clone Shiga-like toxin from the bacterial families Enterobacteriacease and Vibrionacease into E. coli K-12, and to clone a hybrid interleukin-2/diphtheria toxin gene in E. coli K-12. A RAC working group on toxins endorsed both proposals Aug. 16. The NIH advisors will review a revised document submitted by its working group on human gene therapy and public comments received on the draft. The document --"Points to Consider in the Design and Submission of Human Somatic-Cell Gene Therapy Protocols" -- would provide guidance in preparing proposals for NIH consideration. The revised draft contains a new section on "applicability" which was not a part of the document when RAC last considered the proposal.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth